New anti-resorptives and antibody mediated anti-resorptive therapy

Bone and Joint Journal

Volumn 98B, Issue 2, 2016, Pages 160-165

  Farrier, A J ^a   Sanchez Franco, L C ^b   Shoaib, A ^c   Gulati, V ^d   Johnson, N ^e   Uzoigwe, C E ^f   Choudhury, M Z ^g  

^a FREEMAN HOSPITAL   (United Kingdom)

^b STEPPING HILL HOSPITAL   (United Kingdom)

^c HULL ROYAL INFIRMARY   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^f Harcourt House   (United Kingdom)

^g ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING METABOLISM; ANTIRESORPTIVE AGENT; DENOSUMAB; UNCLASSIFIED DRUG; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; SOST PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ANTIBODY MEDIATED ANTIRESORPTIVE THERAPY; ARTICLE; FEMUR FRACTURE; GIANT CELL TUMOR; HYPOCALCEMIA; JAW OSTEONECROSIS; METASTASIS; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THERAPY; ANTAGONISTS AND INHIBITORS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE NEOPLASMS; CHEMICALLY INDUCED; COST BENEFIT ANALYSIS; DRUG APPROVAL; GENETIC MARKER; HUMAN; OSTEOPOROTIC FRACTURES; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; SECONDARY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; BONE RESORPTION; COST-BENEFIT ANALYSIS; DENOSUMAB; DIPHOSPHONATES; DRUG APPROVAL; FEMORAL FRACTURES; GENETIC MARKERS; HUMANS; HYPOCALCEMIA; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RANK LIGAND;

EID: 84958684833     PISSN: 20494394     EISSN: 20494408     Source Type: Journal    
DOI: 10.1302/0301-620X.98B2.36161     Document Type: Article

References (47)

1. http://www.un.org/esa/population/publications/worldageing19502050/pdf/80chapterii.pdf (date last accessed 09 October 2015).
2. White SM, Griffiths R. Projected incidence of proximal femoral fracture in England: A report from the NHS Hip Fracture Anaesthesia Network (HIPFAN). Injury 2011;42:1230-1233
3. Ahmad AS, Ormiston-Smith N, Sasieni PD. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br J Cancer 2015;112:943-947
4. https://www.nice.org.uk/guidance/ta265/resources/guidancedenosumab-for-the-prevention-of-skeletalrelated-events-in-adults-with-bonemetastases-from-solid-tumours-pdf (date last accessed 09 October 2015).
5. https://www.nice.org.uk/guidance/ta204/resources/guidancedenosumab-for-the-prevention-of-osteoporotic-fractures-in-postmenopausalwomen-pdf (date last accessed 09 October 2015).
6. http://www.cancer.gov/cancertopics/druginfo/fda-denosumab (date last accessed 09 October 2015).
7. Shah AD, Shoback D, Lewiecki EM. Sclerostin inhibition: A novel therapeutic approach in the treatment of osteoporosis. Int J Womens Health 2015;7:565-580
8. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-831
9. Grimer R. Denosumab: A drug that you may be hearing a lot more about Bone & Joint 360 2013;2:43-44
10. Lewiecki EM. New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol 2011;7:631-638
11. Wang Z, Qiao D, Lu Y, et al. Systematic Literature Review and Network Meta-Analysis Comparing Bone-Targeted Agents for the Prevention of Skeletal-Related Events in Cancer Patients With Bone Metastasis. Oncologist 2015;20:440-449
12. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: Now and the future. Lancet 2011;377:1276-1287
13. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001120/human-med-001324.jsp&mid=WC0b01ac058001d124 (last accessed 09 October 2015).
14. Messori A, Fadda V, Maratea D, Trippoli S, Marinai C. Anti-reabsorptive agents in women with osteoporosis: Determining statistical equivalence according to evidence-based methods. J Endocrinol Invest 2014;37:769-773
15. Silva-Fernndez L, Rosario MP, Martnez-Lpez JA, Carmona L, Loza E. Denosumab for the treatment of osteoporosis: A systematic literature review. Reumatol Clin 2013;9:42-52
16. Freemantle N, Cooper C, Diez-Perez A, et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: A meta-analysis. Osteoporos Int 2013;24:209-217
17. de Waure C, Specchia ML, Cadeddu C, et al. The prevention of postmenopausal osteoporotic fractures: Results of the Health Technology Assessment of a new antiosteoporotic drug. Biomed Res Int 2014;2014:975927.
18. Darb J, Kaskens L, Sorio Vilela F, Lothgren M. Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. Clinicoecon Outcomes Res 2015;7:105-117
19. Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E. Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Bone 2014;59:105-113
20. Parthan A, Kruse M, Yurgin N, et al. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy 2013;11:485-497
21. http://www.nice.org.uk/guidance/ta160/resources/guidancealendronate-etidronate-risedronate-raloxifene-and-strontium-ranelate-for-the-primary-prevention-of-osteoporotic-fragility-fractures-in-postmenopausal-womenamended-pdf (date last accessed 09 October 2015).
22. Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: A 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012;23:317-326
23. https://www.gov.uk/government/publications/bisphosphonates-use-and-safety/bisphosphonates-use-and-safety (date last accessed 09 October 2015).
24. Anghel R, Bachmann A, Bek?ac M, et al. Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. Wien Klin Wochenschr 2013;125:439-447
25. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28:5132-5139
26. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377:813-822
27. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-1132
28. Sun L, Yu S. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: A systematic review and meta-analysis. Am J Clin Oncol 2013;36:399-403
29. Wang X, Yang KH, Wanyan P, Tian JH. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials. Oncol Lett 2014;7:1997-2002
30. Wang Z, Qiao D, Lu Y, et al. Systematic Literature Review and Network Meta-Analysis Comparing Bone-Targeted Agents for the Prevention of Skeletal-Related Events in Cancer Patients With Bone Metastasis. Oncologist 2015;20:440-449
31. Cheung FH. The practicing orthopedic surgeons guide to managing long bone metastases. Orthop Clin North Am 2014;45:109-119
32. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone 2011;49:71-76
33. Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone - A review and future management considerations. Curr Oncol 2013;20:442-447
34. van der Heijden L, Mastboom MJ, Dijkstra PD, van de Sande MA. Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: A retrospective analysis of 30 patients. Bone Joint J 2014;96-B:1111-1118
35. No author listed. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125320s094lbl.pdf. (date last accessed 09 October 2015).
36. No author listed. https://www.gov.uk/drug-safety-update/denosumab-monitoringrecommended# possible-risk-of-fatal-hypocalcamia. (date last accessed 09 October 2015).
37. Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME. Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis. Cancer Treat Rev 2013;39:97-104
38. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol 2012;23:1341-1347
39. https://www.gov.uk/drug-safety-update/denosumab-updatedrecommendations (date last accessed 12 October 2015).
40. Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG. Atypical femoral fractures and bisphosphonate treatment: Experience in two large United Kingdom teaching hospitals. J Bone Joint Surg [Br] 2012;94-B:385-390
41. Meling T, Nawab A, Harboe K, Fosse L. Atypical femoral fractures in elderly women: A fracture registry-based cohort study. Bone Joint J 2014;96-B:1035-1040
42. https://www.gov.uk/drug-safety-update/denosumab-60-mg-prolia (date last accessed 12 October 2015).
43. SHEF. http://www.shef.ac.uk/NOGG/NOGG-Executive-Summary.pdf. (date last accessed 12 October 2015).
44. No author listed. EMA. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-000145-PIP01-07-M07/pip-000379.jsp&mid=WC0b01ac058001d129 (date last accessed 12 October 2015).
45. Andrews. Denosumab and the treatment of rheumatoid arthritis: In an occupied field, where will a RANKL inhibitor fit in? BoneKEy 2008;5:351-356
46. Cohen SB, Dore RK, Lane NE, et al. Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, doubleblind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-1309
47. Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: Development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int 2015;26:699-712